SNDX

Syndax Pharmaceuticals, Inc. (SNDX) Economic Moat Analysis (2026)

Invetso Score: 2.4/10 — Weak · Last Updated: 2026-08-01

Overall Score

Scale Market Position

Market cap is about $1.74B, which is still small and limits scale advantages.

Revenue per share is $2.83, indicating a modest commercial footprint.

Profitability Returns

Gross margin remains very high at 97.5%, but operating margin is -77.1% and net margin is -87.6%, showing the business is far from durable profitability.

ROIC is -32.1% and ROE is -372.9%, indicating capital is not currently earning attractive returns.

Balance Sheet Resilience

Current ratio is 6.77 and cash ratio is 3.38, so near-term liquidity is strong.

Debt remains heavy relative to capital, with debt-to-capital at 97.5% and financial leverage at 46.6x.

Cash Generation Efficiency

Operating cash flow is negative and free cash flow is negative, so the company is not self-funding from operations.

Cash conversion remains weak, with a cash conversion cycle of 1,722.9 days and inventory turnover of just 0.19x.

Moat Indicators

The company shows no clear evidence of pricing power or durable moat despite a very high gross margin.

Heavy R&D spend at 103.9% of revenue suggests innovation investment, but it has not yet translated into sustained operating leverage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Syndax Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →